Is Ozempic Getting Even More Popular?
A new survey found that almost 13% of U.S. adults are currently taking a new class of weight loss drug, a six percentage point increase from 18 months ago, while one in five U.S. adults, or 18%, report having ever taken one.
Another one in five adults who aren’t using the GLP-1 drugs said they are interested in taking one for weight loss.
The GLP-1 category of drugs, led by Eli Lilly’s Zepbound and Mounjaro and Novo Nordisk’s Ozempic and Wegovy, were only approved in the United States four years ago for the treatment of obesity, but are rapidly becoming the most prescribed drugs. They work by suppressing a gut hormone that controls appetite.
Excerpted from yahoo! news
